ArticleFrontiers in cardiovascular medicine2026
Predictive value of heart rate variability for major adverse cardiovascular events after percutaneous coronary intervention in patients with acute coronary syndrome: a retrospective cohort study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute coronary syndrome (ACS) remains a leading cause of cardiovascular mortality globally. Although percutaneous coronary intervention (PCI) has markedly improved outcomes, the rate of major adverse cardiovascular events (MACE) following PCI remains clinically significant. Heart rate variability (HRV), a noninvasive marker reflecting cardiac autonomic function, may facilitate early risk stratification; however, a systematic evaluation comparing individual time-domain and frequency-domain HRV parameters for predicting MACE after PCI across the full ACS spectrum in the contemporary PCI era is lacking. Methods: This retrospective cohort study enrolled 487 consecutive ACS patients who underwent successful PCI at a single tertiary center between January 2019 and December 2023. Twenty-four-hour Holter monitoring was performed within 72 h post-PCI. Time-domain (SDNN, SDANN, rMSSD, pNN50) and frequency-domain (total power, LF, HF, LF/HF ratio) HRV parameters were analyzed. The primary endpoint was 12-month composite MACE. Univariate and multivariable Cox proportional hazards regression (including analyses stratified by beta-blocker use and an extended model adjusting for troponin, NT-proBNP, renal function and revascularization completeness), receiver operating characteristic (ROC) analysis, Kaplan-Meier survival analysis, and incremental predictive value assessment were performed. Results: During a median follow-up of 11.7 months, 95 patients (19.5%) experienced MACE. The MACE group had significantly lower SDNN (median 85.4 vs. 104.4 ms, Conclusions: SDNN and rMSSD are independent predictors of 12-month MACE in ACS patients following PCI and provide significant incremental prognostic value beyond established clinical risk factors. Because the association between reduced HRV and adverse outcomes is well established, the principal contribution of this contemporary all-ACS cohort is to quantify that association and its added value under current PCI and guideline-directed therapy. Routine HRV assessment may enhance post-PCI risk stratification and guide individualized secondary prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.